Inovio Pharmaceuticals Prices $20 Million Stock Offering
Inovio Pharmaceuticals (INO) has priced an underwritten public offering expected to raise approximately $20 million in gross proceeds. The company plans to issue 21.05 million common shares, along with warrants for up to 42.11 million additional shares at a combined price of $0.95 per share. The announcement led to a significant drop in Inovio's stock price, which slumped by about 22%. The move reflects the company’s ongoing efforts to secure capital amid its development pipeline and financial needs. Such dilutive offerings are often viewed negatively by investors due to concerns over ownership dilution and potential impacts on share value. The market reaction highlights investor skepticism toward equity raises in biotech firms, particularly those not yet profitable or with uncertain revenue streams.
Tickers: $INO